Fresh Tracks Therapeutics, Inc. financial data

Symbol
FRTX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
2000 Central Avenue, Suite 100, Boulder, Colorado
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Brickell Biotech, Inc. (to 9/6/2022), VICAL INC (to 8/30/2019), VICAL, INC. (to 2/11/1994)
Latest financial report
Q4 2023 - Mar 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 597 % +31.3%
Return On Equity -58.8 % +65.1%
Return On Assets -49 % +62.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.97 M shares +1.13%
Common Stock, Shares, Outstanding 5.97 M shares +97.9%
Entity Public Float 4.1 M USD -72.5%
Common Stock, Value, Issued 60 K USD +100%
Weighted Average Number of Shares Outstanding, Basic 5.39 M shares +92.1%
Weighted Average Number of Shares Outstanding, Diluted 5.39 M shares +92.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 8.01 M USD +15.3%
Research and Development Expense 3.18 M USD -77.3%
General and Administrative Expense 11.2 M USD -22.5%
Operating Income (Loss) -6.36 M USD +70.5%
Net Income (Loss) Attributable to Parent -5.69 M USD +73%
Earnings Per Share, Basic -1.06 USD/shares +85.9%
Earnings Per Share, Diluted -1.06 USD/shares +85.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10.9 M USD +25.2%
Other Assets, Current 7 K USD -12.5%
Assets, Current 11.6 M USD +14.6%
Property, Plant and Equipment, Net 34 K USD -54.7%
Operating Lease, Right-of-Use Asset 0 USD -100%
Assets 11.6 M USD +12.8%
Accounts Payable, Current 406 K USD -28.9%
Employee-related Liabilities, Current 232 K USD -82.4%
Accrued Liabilities, Current 1.25 M USD -49.1%
Liabilities, Current 1.66 M USD -46.2%
Retained Earnings (Accumulated Deficit) -172 M USD -3.42%
Stockholders' Equity Attributable to Parent 9.93 M USD +38%
Liabilities and Equity 11.6 M USD +12.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.34 M USD +77.5%
Net Cash Provided by (Used in) Financing Activities 6.53 M USD +454%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 300 M shares 0%
Common Stock, Shares, Issued 5.97 M shares +97.9%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.19 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 10.9 M USD +25.2%
Deferred Tax Assets, Valuation Allowance 132 M USD -0.28%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 132 M USD -0.28%
Operating Lease, Liability 19 K USD -47.2%
Depreciation 41 K USD +36.7%
Lessee, Operating Lease, Liability, to be Paid 19 K USD -48.6%
Operating Lease, Liability, Current 0 USD -100%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1 K USD -50%
Deferred Tax Assets, Operating Loss Carryforwards 106 M USD +1.72%
Operating Lease, Payments 81 K USD -27%
Additional Paid in Capital 182 M USD +4.84%
Preferred Stock, Shares Outstanding 1 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.92 M USD -11%
Interest Expense 5 K USD -44.4%